Evidence map›Paper›PMID 41094203›Full record

ArticleNature immunology2025

Influenza vaccine based on AS03-adjuvanted chimeric HA induces long-lived stalk-specific plasma cells in bone marrow and lymph nodes of nonhuman primates.

Akil Akhtar, Tiffany M Styles, Chunyang Gu, André Nicolás León, Gregory K Tharp, Kasey Stokdyk, Anass Abbad, Cora Hirst, Shirin Strohmeier, Gabriele Neumann and 14 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Nature immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Trial
  2. Review
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

24 authors.

Akil Akhtar *Emory Vaccine Center, Emory National Primate Research Center, Emory University, Atlanta, GA, USA.
Tiffany M Styles *Emory Vaccine Center, Emory National Primate Research Center, Emory University, Atlanta, GA, USA.
Chunyang GuInfluenza Research Institute, Department of Pathobiological Sciences, School of Veterinary Medicine, University of Wisconsin-Madison, Madison, WI, USA.
André Nicolás LeónDepartment of Integrative Structural and Computational Biology, The Scripps Research Institute, La Jolla, CA, USA.
Gregory K TharpEmory Vaccine Center, Emory National Primate Research Center, Emory University, Atlanta, GA, USA.ORCID http://orcid.org/0000-0003-3075-755X
Kasey StokdykEmory Vaccine Center, Emory National Primate Research Center, Emory University, Atlanta, GA, USA.
Anass AbbadDepartment of Microbiology, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Cora HirstDepartment of Biology, Emory University, Atlanta, GA, USA.
Shirin StrohmeierDepartment of Microbiology, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Gabriele NeumannInfluenza Research Institute, Department of Pathobiological Sciences, School of Veterinary Medicine, University of Wisconsin-Madison, Madison, WI, USA.
Sara T RicheyDepartment of Integrative Structural and Computational Biology, The Scripps Research Institute, La Jolla, CA, USA.
James A FergusonDepartment of Integrative Structural and Computational Biology, The Scripps Research Institute, La Jolla, CA, USA.
Uchurappa MalaEmory Vaccine Center, Emory National Primate Research Center, Emory University, Atlanta, GA, USA.
Hasan AhmedDepartment of Biology, Emory University, Atlanta, GA, USA.
Julianna HanDepartment of Integrative Structural and Computational Biology, The Scripps Research Institute, La Jolla, CA, USA.ORCID http://orcid.org/0000-0002-3402-2609
Juan Manuel CarreñoDepartment of Microbiology, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Carl W DavisEmory Vaccine Center, Emory National Primate Research Center, Emory University, Atlanta, GA, USA.ORCID http://orcid.org/0000-0002-6049-0684
Rustom AntiaDepartment of Biology, Emory University, Atlanta, GA, USA.ORCID http://orcid.org/0000-0001-7991-614X
Peter PaleseDepartment of Microbiology, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Andrew B WardDepartment of Integrative Structural and Computational Biology, The Scripps Research Institute, La Jolla, CA, USA.ORCID http://orcid.org/0000-0001-7153-3769
Yoshihiro KawaokaInfluenza Research Institute, Department of Pathobiological Sciences, School of Veterinary Medicine, University of Wisconsin-Madison, Madison, WI, USA.ORCID http://orcid.org/0000-0001-5061-8296
Florian KrammerDepartment of Microbiology, Icahn School of Medicine at Mount Sinai, New York, NY, USA.ORCID http://orcid.org/0000-0003-4121-776X
Rafi AhmedEmory Vaccine Center, Emory National Primate Research Center, Emory University, Atlanta, GA, USA.ORCID http://orcid.org/0000-0002-9591-2621
Rama R AmaraEmory Vaccine Center, Emory National Primate Research Center, Emory University, Atlanta, GA, USA. ramara@emory.edu.ORCID http://orcid.org/0000-0002-6309-6797

Funding

Yerkes National Primate Research Center Role of type-I IFN in regulating COVID-19 induced inflammation and pathogenesisP51OD011132 · OD · EMORY UNIVERSITY · PI Joon Sup Lee · 2012 to 2026
$167.0M
COLLABORATIVE INFLUENZA VACCINE INNOVATION CENTER: UNIVERSAL INFLUENZA VACCINE RESEARCH75N93019C00051 · NIAID · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI KRAMMER, FLORIAN · 2019 to 2025
$105.4M
B and T Cell Biology of Protection from and Eradication of SIV/SHIV InfectionUM1AI169662 · NIAID · EMORY UNIVERSITY · PI Rama Rao Amara, Eric Hunter · 2022 to 2026
$32.0M
NIAID NIH HHS 75N93019C00051NIAID NIH HHS UM1 AI169662NIH HHS P51 OD011132
6 · The paper itself

Abstract

Current influenza vaccines face challenges due to antigenic evolution of the circulating virus and waning immunity in humans. Here we investigated the durability of humoral immunity induced by an influenza vaccine based on AS03-adjuvanted chimeric hemagglutinin (cHA) in nonhuman primates (NHPs). Two groups of NHPs received two doses of a seasonal quadrivalent influenza vaccine, followed by sequential immunization with split virus cHA vaccines cH8/1N1, and cH5/1N1. One group received cHA immunizations with AS03 adjuvant. We monitored serum antibodies and long-lived plasma cells in bone marrow for nearly 2 years after the final vaccination. cHA vaccines induced stalk-specific antibody responses. The addition of AS03 enhanced both the magnitude and durability of humoral immunity by establishing long-lived plasma cells in the bone marrow and lymph nodes for nearly 2 years. Passive transfer of NHP serum provided protection against challenge with heterologous influenza A virus strains in mice. This study highlights the potential of the AS03-adjuvanted chimeric HA vaccine strategy to provide durable and broadly protective humoral immunity.

Indexed as

alpha-TocopherolHemagglutinin Glycoproteins, Influenza VirusInfluenza VaccinesLymph NodesOrthomyxoviridae InfectionsPlasma CellsPolysorbatesSqualeneAdjuvants, ImmunologicAnimalsAntibodies, ViralBone MarrowDrug CombinationsFemaleHumansImmunity, HumoralAdjuvants, Immunologicalpha-TocopherolAntibodies, ViralAS03 adjuvantDrug CombinationsHemagglutinin Glycoproteins, Influenza VirusInfluenza VaccinesPolysorbatesSqualene

Identifiers

PMID41094203
PMCPMC12571899

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.